Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Operating Expenses (2021 - 2025)

Prime Medicine (PRME) has disclosed Operating Expenses for 5 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 6.55% year-over-year to $49.4 million, compared with a TTM value of $213.0 million through Dec 2025, up 3.67%, and an annual FY2025 reading of $213.0 million, up 3.67% over the prior year.
  • Operating Expenses was $49.4 million for Q4 2025 at Prime Medicine, down from $55.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $68.0 million in Q4 2023 and bottomed at $7.2 million in Q4 2021.
  • Average Operating Expenses over 5 years is $42.1 million, with a median of $47.7 million recorded in 2024.
  • The sharpest move saw Operating Expenses skyrocketed 438.28% in 2022, then tumbled 31.8% in 2024.
  • Year by year, Operating Expenses stood at $7.2 million in 2021, then surged by 438.28% to $38.7 million in 2022, then skyrocketed by 75.89% to $68.0 million in 2023, then tumbled by 31.8% to $46.4 million in 2024, then rose by 6.55% to $49.4 million in 2025.
  • Business Quant data shows Operating Expenses for PRME at $49.4 million in Q4 2025, $55.2 million in Q3 2025, and $54.5 million in Q2 2025.